Neoadjuvant Chemotherapy Followed by Radiation Therapy and Gemcitabine/Sorafenib/Vorinostat in Pancreatic Cancer
Last updated on July 2021Recruitment
- Recruitment Status
- Active, not recruiting
- Estimated Enrollment
- 36
Summary
- Conditions
- Pancreatic Adenocarcinoma
- Recurrent Pancreatic Carcinoma
- Stage IA Pancreatic Cancer
- Stage IB Pancreatic Cancer
- Stage IIA Pancreatic Cancer
- Stage IIB Pancreatic Cancer
- Stage III Pancreatic Cancer
- Type
- Interventional
- Phase
- Phase 1
- Design
- Allocation: N/AIntervention Model: Single Group AssignmentMasking: None (Open Label)Primary Purpose: Treatment
Participation Requirements
- Age
- Between 18 years and 125 years
- Gender
- Both males and females
Description
To determine the doses and schedule appropriate for phase 2 study of sorafenib and vorinostat with concurrent gemcitabine and radiation therapy (RT) as neoadjuvant treatment of pancreatic cancer following chemotherapy. RP2Ds and schedule of sorafenib and vorinostat defined as the doses and schedule ...
To determine the doses and schedule appropriate for phase 2 study of sorafenib and vorinostat with concurrent gemcitabine and radiation therapy (RT) as neoadjuvant treatment of pancreatic cancer following chemotherapy. RP2Ds and schedule of sorafenib and vorinostat defined as the doses and schedule that are the same as or less than the MTDs and schedule. This is a dose-escalation trial employing a standard "3+3" schema of sorafenib and vorinostat. The sample size with a total of 5 proposed dose levels and starting at dose level 1B for dose escalation, the number of patients evaluable for DLT ranges from 4-30. To account for about 20% patients anticipated to subsequently be found to be not evaluable for toxicity, authorization for enrollment of 36 patients will be sought from regulatory authorities. Likely scenarios probably involve 12-24 evaluable patients and therefore 15-30 patients will be enrolled in the study. After completion of study treatment, patients are followed up for 30 days and then every 2-3 months up to 2 years or until death.
Tracking Information
- NCT #
- NCT02349867
- Collaborators
- National Cancer Institute (NCI)
- Investigators
- Principal Investigator: Andrew Poklepovic, MD Massey Cancer Center